Skip to Content

Publications

Myeloproliferative Disorders (MPD)

Leukemia Insights - Spring 2007

The development of novel therapies for patients with MPD has been historically hampered by limited understanding of the abnormal processes and molecular causes of these diseases. The discovery of JAK2 mutation in most MPD patients is a first step in this direction. Agents potentially able to interfere with identified abnormalities in MPD are becoming available. Participation in clinical trials of novel agents is warranted. Available programs are listed below.
Therapy

MF

ET

PV

Open to Patients

Pegylated Interferon α (Pegasys)

 

X

X

X

Revlimid (Lenalidomide ) + Prednisone

X

 

 

X

Bortezomib (Velcade)

X

 

 

X

Dasatinib (Sprycel)

 X

 

X

X

Obatoclax (pan bcl-2 inhibitor)

X

 

 

X

Sunitinib (Suniteb)

X

 

 

X

GC-1008 (antibody against TGF-b)

X

 

 

March-April 2007

Pomalidomide (CC-4047)

X

 

 

March-April 2007

JAK2 inhibitor

X

 

 

March-April 2007

For additional information about the therapies for MPD at M. D. Anderson Cancer Center, visit the myeloproliferative disorders page or contact Srdan Verstovsek, MD, PhD, MPD Program Leader, at (713) 745-3429; e-mail sverstov@mdanderson.org.


© 2014 The University of Texas MD Anderson Cancer Center